SGO Issues May 15, 2014
SGO quality measures pass CoC vote
SGO report on gyn cancer disparities published
Upgrading to the next level of SGO Membership
Clarification: SGO perspective on ASTRO guideline
Fundraising social photos now on Flickr
On May 1, the American College of Surgeons’ Commission on Cancer’s (CoC) Quality Integration Committee approved seven SGO ovarian, endometrial and cervical quality indicators, paving the way for SGO and CoC to submit the measures to the National Quality Forum (NQF) for endorsement as CMS PQRS measures.
The following quality measures were approved based on data from the National Cancer Database.
- Use of brachytherapy in patients treated with primary radiation with curative intent in any stage of cervical cancer
- Radiation therapy completed within 60 days of initiation of radiation among women diagnosed with any stage of cervical cancer
- Chemotherapy administered to cervical cancer patients with stages IB2-IV cancer or with positive pelvic nodes, positive surgical margin, and/or positive parametrium
- Endoscopic, laparoscopic, or robotic surgery performed for all endometrial cancer (excluding sarcoma and lymphoma), for all stages (excluding stage IVs)
- Chemotherapy and/or radiation administered to patients with stage IIIC or IV endometrial cancer
- Salpingo-oophorectomy with omentectomy, debulking; cytoreductive surgery, or pelvic exenteration in stages I-IIIC ovarian cancer
- Chemotherapy started within 42 days before or after the date of most definite surgery in stages IA-IV ovarian, fallopian tube, or peritoneal cancers
The CoC will report the approved gynecologic oncology measures to the 1,500 CoC-accredited programs through their Cancer Programs Practice Profile Reports (CP3R) and Rapid Quality Reporting Systems (RQRS) on a yearly basis. The SGO will continue to work with the CoC to incorporate additional gynecologic oncology fields for the next revision of the Facility Oncology Registry Data Standards (FORDS) Manual, which determines the content of the National Cancer Database.
SGO Quality and Outcomes Committee Chair Matthew A. Powell, MD, of Washington University in St. Louis, MO, noted that these measures are currently collected within the NCDB.
“We are looking forward to expanding our other quality measures that have been developed to also be collected by the CoC/NCDB in the future,” said Dr. Powell. “The Quality and Outcomes Committee will work to have additional data be part of the NCDB.”
SGO Quality and Outcomes Committee member Summer Dewdney, MD, of Rush University Medical Center in Chicago noted that the CoC accredits over 1,500 cancer sites that treat more than 70 percent of the cancer diagnoses in the US, including both community and tertiary care centers.
“Implementing these quality measures in the COC accredited institutions will likely make a huge impact on the quality of care for women with gynecologic cancers,” she said.
The May 2014 edition of Gynecologic Oncology includes a report by an SGO taskforce headed by Yvonne Collins, MD: “Gynecologic cancer disparities: A report from the Health Disparities Taskforce of the Society of Gynecologic Oncology.” Additional taskforce members are Kevin Holcomb, MD; Eloise Chapman-Davis, MD; Dineo Khabele, MD; and John H. Farley, MD, FACOG, FACS.
Applications are due July 31 for SGO members who are eligible to upgrade to the next level of membership.
- Those who have recently obtained board certification in gynecologic oncology are now eligible for Full Membership
- Fellow-in-Training Members scheduled to graduate this summer must apply for a Candidate Membership to maintain their member benefits. Apply before July 31, 2014 to save $50 off the first year of Candidate Member dues.
- SGO also encourages newly matched Fellows to apply for Fellow-in-Training Membership.
Contact email@example.com with any questions about membership applications.
In the May/June 2014 issue of Practical Radiation Oncology, the American Society for Therapeutic Radiation and Oncology (ASTRO) indicated that SGO endorsed ASTRO’s guideline on postoperative radiation therapy for endometrial cancer. To clarify, SGO did not endorse the guideline but rather provided closely aligned perspective in an accompanying editorial, “Postoperative radiation therapy for endometrial cancer: Where do we go from here?”
Photos from the SGO Foundation Fundraising Social, Mad About Women’s Cancer Care, from the 2014 SGO Annual Meeting in Tampa, FL, are now available on SGO’s Flickr account.